Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0015436031
Wed, 08.06.2022
CureVac
CureVac Accelerates Oncology Strategy with Acquisition of Frame Cancer Therapeutics, Adding Novel Antigen Discovery Platform
Acquisition extends CureVac’s capabilities and adds key competencies to further accelerate oncology strategy for new therapies that enable patients’ immune systems to fight cancer
Frame’s platform offers potential to dev [ … ]
Wed, 08.06.2022
CureVac
CureVac Announces Changes of CDO - Myriam Mendila to succeed Klaus Edvardsen
Myriam Mendila appointed as Chief Development Officer starting from February 1, 2023
Klaus Edvardsen returning to Denmark after holding numerous leadership positions in the U.S. and Europe
Ulrike Gnad-Vogt, Senior Vice President Area Head Oncology, will act as interi [ … ]
Wed, 25.05.2022
CureVac
CureVac Announces Financial Results for the First Quarter of 2022 and Provides Business Update
Progressing broad vaccine development program in collaboration with GSK, with second-generation candidates in Phase 1 clinical trials for COVID-19 and influenza
CureVac eligible to a €10 million milestone payment from GSK for the initiation of the influ [ … ]
Wed, 25.05.2022
CureVac
CureVac Partners with myNEO to Identify Novel Antigen Targets for mRNA-Based Cancer Vaccine Development
CureVac is broadening its foundation in oncology, leveraging recent progress with its second-generation mRNA backbone
The partnership combines CureVac’s mRNA technology with myNEO’s platform for the discovery and selection of tumor antigens pre [ … ]
Thu, 28.04.2022
CureVac
CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2021 and Provides Business Update
- Executing on broad vaccine development program, with new clinical studies in COVID-19 and influenza together with GSK to validate advanced second-generation mRNA backbone
- Initiated Phase 1 dose-escalation study in COVID-19 with CV2CoV, v [ … ]
Fri, 22.04.2022
CureVac
CureVac to Report Fourth Quarter and Full-Year 2021 Financial Results and Business Updates on April 28, 2022
TÜBINGEN, Germany/ BOSTON, USA - April 22, 2022 - CureVac N.V. (Nasdaq: CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), will report financial results, and p [ … ]
Thu, 21.04.2022
CureVac
CureVac and GSK's Bivalent Second-Generation mRNA Vaccine Candidate Shown to be Highly Effective Against SARS-CoV-2 Variants in Preclinical Study
- Vaccine candidate combining Beta- and Delta-specific mRNAs shows strong protection and immune responses during preclinical challenge study
- Demonstrated neutralizing capacity against the Omicron vari [ … ]
Mon, 11.04.2022
CureVac
CureVac and GSK Enter into Pandemic Preparedness Contract with German Government
- German government reserves domestic manufacturing capacity until 2029 to ensure rapid access to mRNA vaccines developed by CureVac and GSK
- Five-year contract enables production of up to 80 million vaccine doses at short notice in case of a public health emergency [ … ]
Wed, 30.03.2022
CureVac
CureVac and GSK Start Clinical Development of Second-Generation COVID-19 Vaccine Candidate, CV2CoV
- Phase 1 dose-escalation study started at clinical sites in the U.S.
- Milestone demonstrates CureVac's and GSK's continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases
TÜBINGEN, Germa [ … ]
Tue, 01.03.2022
CureVac
CureVac Establishes Fully-Owned Company Dedicated to Advancing The RNA Printer(R)
- The RNA Printer(R) is CureVac's integrated and automated manufacturing solution for RNA vaccines and therapeutics
- CureVac RNA Printer GmbH to provide dedicated infrastructure to accelerate development and broaden application range of The RNA Printer(R)
- Dr. Ma [ … ]